Antibiotic Can Reduce Hospitalization, Prevent Recurrence of Rare Brain Disorder, Analysis Shows

Mar 26, 2010

(PhysOrg.com) -- A study analysis by researchers at the University of Cincinnati confirms that the antibiotic rifaximin can reduce hospitalizations for patients and prevent the recurrence of a certain brain disorder caused by liver failure.

A study analysis by researchers at the University of Cincinnati confirms that the antibiotic rifaximin can reduce hospitalizations for patients and prevent the recurrence of a certain brain disorder caused by .

These findings were reported in the March 25, 2010, edition of the .

Guy Neff, MD, lead investigator on the study locally and associate professor of medicine, and transplant, with colleagues in the digestive diseases division, found that rifaximin significantly reduced the risk of hepatic encephalopathy-related hospitalizations when compared to a placebo drug.

In addition, over a six-month period, treatment with rifaximin helped patients maintain remission for hepatic encephalophaty more effectively than the placebo.

Hepatic encephalopathy, or HE, is a potentially reversible neuropsychiatric abnormality that can result due to liver failure.

"When there is severe damage to the liver, toxic substances that are normally removed by the liver accumulate in the blood and impair the brain,” says Neff, director of liver transplantation and a specialist with UC Health. "Signs of HE can include impaired cognition, asterixis—or a wrist tremor—and a decreased level of consciousness including coma, cerebral edema and possibly death.”

Rifaximin is approved to treat traveler’s diarrhea. On March 24, 2010, the U.S. also approved this drug for the unrestricted treatment of HE—the first new treatment for the disorder in over 30 years.

Researchers analyzed a randomized, double-blind, placebo-controlled study of 299 patients with a history of HE—meaning patients and researchers were not told whether they were receiving/giving rifaximin or the placebo drug.

They found that patients who took rifaximin as opposed to the placebo had about 50 percent less risk of being hospitalized; also, approximately 58 percent of patients given the drug did not experience recurrence of HE.

"This new data solidly supports the clinical efficacy of rifaximin in reducing the risk of HE-related hospitalization and its ability to prevent patients from redeveloping the illness,” Neff says. "As demonstrated in previously published pharmacoeconomic data, reducing recurrent HE events may reduce the need for HE-related hospitalization, thereby potentially decreasing the costs of care, and improving patients' quality of life.”

Neff has received honoraria from the makers of rifaximin.

Explore further: Research shows that bacteria survive longer in contact lens cleaning solution than thought

More information: Study paper: content.nejm.org/cgi/reprint/362/12/1071.pdf

add to favorites email to friend print save as pdf

Related Stories

Ibuprofen restores learning ability in rats with liver failure

Aug 01, 2007

Cognitive impairment is one of the neurological effects in patients with hepatic encephalopathy (abnormal brain function due to severe liver disease). For the first time, a new study showed that treatment with an anti-inflammatory ...

Mayo Clinic seeks new therapies for alcoholic hepatitis

Dec 01, 2008

A new study from Mayo Clinic finds the use of the drug therapy etanercept ineffective in treating alcoholic hepatitis, an acute inflammation of the liver caused by excessive consumption of alcohol. The results of the study ...

Recommended for you

Ebola virus in Africa outbreak is a new strain

7 hours ago

The Ebola virus that has killed scores of people in Guinea this year is a new strain—evidence that the disease did not spread there from outbreaks in some other African nations, scientists report.

Researchers see hospitalization records as additional tool

7 hours ago

Comparing hospitalization records with data reported to local boards of health presents a more accurate way to monitor how well communities track disease outbreaks, according to a paper published April 16 in the journal PLOS ON ...

User comments : 0

More news stories

Down's chromosome cause genome-wide disruption

The extra copy of Chromosome 21 that causes Down's syndrome throws a spanner into the workings of all the other chromosomes as well, said a study published Wednesday that surprised its authors.

Simplicity is key to co-operative robots

A way of making hundreds—or even thousands—of tiny robots cluster to carry out tasks without using any memory or processing power has been developed by engineers at the University of Sheffield, UK.

Progress in the fight against quantum dissipation

(Phys.org) —Scientists at Yale have confirmed a 50-year-old, previously untested theoretical prediction in physics and improved the energy storage time of a quantum switch by several orders of magnitude. ...